Iterum Therapeutics Plc. (ITRM) NASDAQ

$0.25 0.01 (2.13%)

Market Cap: $44.76M

As of 08/10/22 04:00 PM EDT. Market closed.

(ITRM)

Iterum Therapeutics Plc. (ITRM) NASDAQ

$0.25 0.01 (2.13%)

Market Cap: $44.76M

As of 08/10/22 04:00 PM EDT. Market closed.

Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective ... read more

Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
URL
Address
.
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
Full Time Employees
7
Address
.
PRICE CHART
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
KEY STATS
Open
$0.26
Previous Close
$0.24
Days Range
$0.20 - $0.27
52 week range
$0.18 - $0.75
Volume
1,297,855
Avg. Volume (30 days)
2,172,681
Market Cap
$44.76M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
183,353,418
Open
$0.26
Previous Close
$0.24
Days Range
$0.20 - $0.27
52 week range
$0.18 - $0.75
Volume
1,297,855
Avg. Volume (30 days)
2,172,681
Market Cap
$44.76M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
183,353,418

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR ITERUM THERAPEUTICS PLC
Owner Relationship Date Transaction Cost # Shares Value($) Total Shares Form 4
Matthews Judith M. Chief Financial Officer Mar 14, 2022 Sale $0.31 63,340 19,635 65,292 Mar 15, 2022, 07:12 PM
Matthews Judith M. Chief Financial Officer Mar 14, 2022 Sale $0.38 47,132 17,910 81,500 Mar 15, 2022, 05:01 PM
DENNER ALEXANDER J 10% Owner Feb 12, 2021 Sale $2.27 10,619,949 24,107,284 0 Feb 12, 2021, 08:22 PM
DENNER ALEXANDER J 10% Owner Feb 11, 2021 Sale $2.59 10,000,000 25,899,999 10,619,949 Feb 12, 2021, 08:22 PM
Fishman Corey N. President & CEO Jan 26, 2021 Sale $1.73 85,445 147,820 322,008 Jan 27, 2021, 07:35 PM
Dunne Michael W. Director Jan 26, 2021 Sale $1.73 33,143 57,337 256,355 Jan 27, 2021, 07:32 PM
Matthews Judith M. Chief Financial Officer Jan 26, 2021 Sale $1.73 33,868 58,592 28,632 Jan 27, 2021, 07:32 PM
Matthews Judith M. Chief Financial Officer Sep 30, 2020 Sale $1.64 56,130 92,053 0 Oct 02, 2020, 09:00 PM
Sofinnova Venture Partners IX, L.P. 10% Owner Jun 02, 2020 Sale $1.61 400,000 642,960 1,226,514 Jun 03, 2020, 08:20 PM
Sofinnova Venture Partners IX, L.P. 10% Owner Jun 01, 2020 Sale $1.69 100,000 169,120 1,626,514 Jun 03, 2020, 08:20 PM
Kelly David George Director Nov 30, 2018 Buy $6.29 10,000 62,887 19,548 Dec 04, 2018, 05:48 PM
Chin Mark Director Oct 30, 2018 Buy $6.10 58,000 353,800 1,089,903 Nov 01, 2018, 05:25 PM
Dunne Michael W. Chief Scientific Officer Sep 04, 2018 Buy $10.00 500 5,000 147,958 Sep 06, 2018, 05:11 PM
Dunne Michael W. Chief Scientific Officer Aug 27, 2018 Buy $10.00 500 5,000 147,458 Aug 28, 2018, 05:18 PM
Dunne Michael W. Chief Scientific Officer Aug 24, 2018 Buy $10.00 500 5,000 146,958 Aug 28, 2018, 05:18 PM
Edick Paul R Director Aug 23, 2018 Buy $10.44 500 5,219 25,236 Aug 27, 2018, 05:15 PM
Fishman Corey N. President & CEO Aug 17, 2018 Buy $8.73 2,000 17,466 239,953 Aug 21, 2018, 10:44 AM
Chin Mark Director May 30, 2018 Buy $13.00 337,606 4,388,878 1,031,903 Jun 01, 2018, 03:37 PM
Lathi Vijay K 10% Owner May 30, 2018 Buy $13.00 384,615 4,999,995 384,615 May 31, 2018, 04:54 PM
Lathi Vijay K 10% Owner May 30, 2018 Buy $13.00 278,062 3,614,806 1,071,688 May 31, 2018, 04:54 PM
HUNT RONALD Director May 30, 2018 Buy $13.00 384,615 4,999,995 384,615 May 31, 2018, 04:52 PM
HUNT RONALD Director May 30, 2018 Buy $13.00 278,062 3,614,806 1,071,688 May 31, 2018, 04:52 PM
Sofinnova Venture Partners IX, L.P. 10% Owner May 30, 2018 Buy $13.00 500,000 6,500,000 1,726,514 May 30, 2018, 09:59 PM
HEALY JAMES Director May 30, 2018 Buy $13.00 500,000 6,500,000 1,726,514 May 30, 2018, 05:32 PM
Malik Shahzad Director May 30, 2018 Buy $13.00 228,840 2,974,920 838,325 May 30, 2018, 05:29 PM
Malik Shahzad Director May 30, 2018 Buy $13.00 8,144 105,872 29,836 May 30, 2018, 05:29 PM
Ahrens Brenton Karl Director May 30, 2018 Buy $13.00 506,656 6,586,528 1,733,170 May 30, 2018, 05:26 PM
CANAAN X L.P. Director May 30, 2018 Buy $13.00 506,656 6,586,528 1,733,170 May 30, 2018, 05:25 PM
Heron Patrick J Director May 30, 2018 Buy $13.00 101,150 1,314,950 341,155 May 30, 2018, 05:15 PM
Heron Patrick J Director May 30, 2018 Buy $13.00 354,949 4,614,337 1,197,161 May 30, 2018, 05:15 PM
Matthews Judith M. Chief Financial Officer May 30, 2018 Buy $13.00 4,000 52,000 56,130 May 30, 2018, 05:12 PM
Dunne Michael W. Chief Scientific Officer May 30, 2018 Buy $13.00 2,000 26,000 146,458 May 30, 2018, 05:02 PM
Fishman Corey N. President & CEO May 30, 2018 Buy $13.00 3,000 39,000 237,953 May 30, 2018, 05:01 PM
Load More Insider Transactions
Buy Sale Option Exercise
Owner Relationship Date Value($)
Matthews Judith M. Chief Financial Officer 03/14/2022 19,635
Matthews Judith M. Chief Financial Officer 03/14/2022 17,910
DENNER ALEXANDER J 10% Owner 02/12/2021 24,107,284
DENNER ALEXANDER J 10% Owner 02/11/2021 25,899,999
Fishman Corey N. President & CEO 01/26/2021 147,820
Dunne Michael W. Director 01/26/2021 57,337
Matthews Judith M. Chief Financial Officer 01/26/2021 58,592
Matthews Judith M. Chief Financial Officer 09/30/2020 92,053
Sofinnova Venture Partners IX, L.P. 10% Owner 06/02/2020 642,960
Sofinnova Venture Partners IX, L.P. 10% Owner 06/01/2020 169,120
Kelly David George Director 11/30/2018 62,887
Chin Mark Director 10/30/2018 353,800
Dunne Michael W. Chief Scientific Officer 09/04/2018 5,000
Dunne Michael W. Chief Scientific Officer 08/27/2018 5,000
Dunne Michael W. Chief Scientific Officer 08/24/2018 5,000
Edick Paul R Director 08/23/2018 5,219
Fishman Corey N. President & CEO 08/17/2018 17,466
Chin Mark Director 05/30/2018 4,388,878
Lathi Vijay K 10% Owner 05/30/2018 4,999,995
Lathi Vijay K 10% Owner 05/30/2018 3,614,806
HUNT RONALD Director 05/30/2018 4,999,995
HUNT RONALD Director 05/30/2018 3,614,806
Sofinnova Venture Partners IX, L.P. 10% Owner 05/30/2018 6,500,000
HEALY JAMES Director 05/30/2018 6,500,000
Malik Shahzad Director 05/30/2018 2,974,920
Malik Shahzad Director 05/30/2018 105,872
Ahrens Brenton Karl Director 05/30/2018 6,586,528
CANAAN X L.P. Director 05/30/2018 6,586,528
Heron Patrick J Director 05/30/2018 1,314,950
Heron Patrick J Director 05/30/2018 4,614,337
Matthews Judith M. Chief Financial Officer 05/30/2018 52,000
Dunne Michael W. Chief Scientific Officer 05/30/2018 26,000
Fishman Corey N. President & CEO 05/30/2018 39,000
Load More Insider Transactions
CHANGE IN SHARES OUTSTANDING
STOCK BUYBACKS
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
12/31/2021
09/30/2021
4.68%
1Q
12/31/2021
06/30/2021
12.97%
2Q
12/31/2021
03/31/2021
34.40%
3Q

Period of Report: 12/31/2021

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
09/30/2021
4.68%
1Q
06/30/2021
12.97%
2Q
03/31/2021
34.40%
3Q